Skip to Main Content

Zachary Corbin, MD, MHS

Assistant Professor; Director, Neuro-Oncology Fellowship Program, Neurology

Contact Information

Zachary Corbin, MD, MHS

Research Summary

Dr. Corbin's overarching research goal is to combine neuroimaging and cancer biology to improve both the quality of life and longevity of patients suffering from neuro-oncologic disease.

Extensive Research Description

His clinical research career began as a medical student at Yale, and he then earned a student research fellowship to study at the Massachusetts General Hospital. He trained as a neurologist at the University of California, San Francisco and then completed Neuro-Oncology Fellowship at Stanford University. At Stanford, he led a study employing positron emission tomography (PET)/MRI in patients with glioblastoma who received bevacizumab.

He was recruited back to Yale to develop the program in metabolic imaging in neuro-oncology. With his colleagues at the Yale Magnetic Resonance Research Center, he has deployed deuterium metabolic imaging (DMI) in patients with primary brain tumors. He has since developed a multi-modality imaging technique using PET and magnetic resonance spectroscopy (MRS) called the Warburg Index. He and his colleagues aim to measure metabolic changes in gliomas with a particular mutation in isocitrate dehydrogenase (IDH).

Research Interests

Brain; Brain Neoplasms; Metabolism

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma
Brain and Nervous System; PediatricsA Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Brain and Nervous SystemA Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Brain and Nervous SystemGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Brain and Nervous SystemPhase 1: BGB-290 in combination with TMZ in patients w/ IDH1/2-mutant WHO grade II-IV recurrent glioma: Phase 2: Grade II-III patients in will be stratified into 2 arms based on the timing of prior alkylator chemotherapy exposure; a third arm will include the subset of glioblastoma (grade IV) patients
Brain and Nervous SystemGenomically-Guided Treatment Trial in Brain Metastases
Brain and Nervous SystemPhase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Brain and Nervous SystemPhase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Brain and Nervous SystemPhase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma